[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 444
Citations 0
Comment & Response
June 25, 2014

Therapies for Venous Thromboembolism—Reply

Author Affiliations
  • 1Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
JAMA. 2014;311(24):2543-2544. doi:10.1001/jama.2014.6123

In Reply We are aware that the FDA and other agencies may not have approved all of the new oral anticoagulants for the treatment of venous thromboembolism; however, many jurisdictions have. The purpose of Table 1 was not to list drugs that have received agency approval but rather to list drugs that have evidence behind their use.

The PEITHO study1 was not published when we wrote our review (although it has been published since), and we chose not to describe in detail data only available from an abstract. Furthermore, given the complexity and cost of thrombolytic therapy, we focused on mortality as the most likely outcome to affect practice. We acknowledge that the study was positive for the primary end point.

First Page Preview View Large
First page PDF preview
First page PDF preview
×